{"id":"formoterol-inhalation-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Nervousness"}]},"_chembl":{"chemblId":"CHEMBL1256786","moleculeType":"Small molecule","molecularWeight":"344.41"},"_dailymed":{"setId":"2d9bf685-8886-4865-834b-2748af124b79","title":"FORMOTEROL FUMARATE INHALATION SOLUTION (FORMOTEROL FUMARATE DIHYDRATE) SOLUTION [RITEDOSE PHARMACEUTICALS, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and airway dilation. As a long-acting formulation, it provides sustained bronchodilation for 12 hours or longer, making it suitable for maintenance therapy in chronic obstructive airway diseases. The inhalation solution formulation allows direct delivery to the lungs for rapid local effect.","oneSentence":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:00.833Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma (maintenance therapy)"}]},"trialDetails":[{"nctId":"NCT04886999","phase":"PHASE3","title":"Study in Adult Patients With Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-02-24","conditions":"Asthma","enrollment":78},{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT06786767","phase":"","title":"Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting","status":"COMPLETED","sponsor":"Chiesi Bulgaria","startDate":"2025-02-01","conditions":"Asthma, Asthma Patients, Asthma Bronchiale","enrollment":281},{"nctId":"NCT07450482","phase":"PHASE2","title":"Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2025-07-22","conditions":"COPD (Chronic Obstructive Pulmonary Disease), COPD","enrollment":42},{"nctId":"NCT07022418","phase":"PHASE2","title":"Formoterol in Diabetes","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-12-01","conditions":"Diabetic Nephropathies, Diabetic Kidney Disease","enrollment":120},{"nctId":"NCT04320342","phase":"PHASE3","title":"A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-04-28","conditions":"COPD, COPD Exacerbation","enrollment":3433},{"nctId":"NCT05292586","phase":"PHASE3","title":"A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-08-31","conditions":"Asthma","enrollment":1377},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":"Atopic Rhinitis, Atopic Asthma","enrollment":200},{"nctId":"NCT06234345","phase":"PHASE3","title":"Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1252},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT03086460","phase":"PHASE2","title":"A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-09-08","conditions":"Asthma","enrollment":67},{"nctId":"NCT04737655","phase":"PHASE4","title":"Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care","status":"UNKNOWN","sponsor":"PARZIBUT Gilles","startDate":"2021-02-15","conditions":"COPD Exacerbation","enrollment":200},{"nctId":"NCT03842904","phase":"PHASE4","title":"A Study Comparing the Effects of Trimbow to Fostair in COPD","status":"COMPLETED","sponsor":"Medicines Evaluation Unit Ltd","startDate":"2018-12-13","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":23},{"nctId":"NCT02291016","phase":"NA","title":"COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers","status":"COMPLETED","sponsor":"University of Tennessee Graduate School of Medicine","startDate":"2015-02","conditions":"COPD Exacerbation","enrollment":7},{"nctId":"NCT02275481","phase":"PHASE4","title":"A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":66},{"nctId":"NCT00862394","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-02","conditions":"Asthma","enrollment":783},{"nctId":"NCT02796651","phase":"PHASE2","title":"Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-30","conditions":"Chronic Obstructive Pulmonary Disease - COPD","enrollment":132},{"nctId":"NCT01854047","phase":"PHASE2","title":"An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Asthma","enrollment":776},{"nctId":"NCT01488019","phase":"PHASE4","title":"Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)","status":"COMPLETED","sponsor":"Dey","startDate":"2012-03","conditions":"COPD","enrollment":1071},{"nctId":"NCT02347072","phase":"PHASE3","title":"24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-02-01","conditions":"COPD","enrollment":80},{"nctId":"NCT00633776","phase":"PHASE4","title":"Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2008-03","conditions":"Chronic Obstructive Pulmonary Disease, COPD, Chronic Bronchitis","enrollment":""},{"nctId":"NCT01857479","phase":"PHASE2, PHASE3","title":"A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2013-05","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":21},{"nctId":"NCT01013753","phase":"PHASE2","title":"A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-02","conditions":"Asthma","enrollment":198},{"nctId":"NCT00909779","phase":"PHASE3","title":"Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":841},{"nctId":"NCT01168310","phase":"PHASE2","title":"A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Dey","startDate":"2010-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":468},{"nctId":"NCT01113593","phase":"PHASE2","title":"A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Dey","startDate":"2010-05","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT00774761","phase":"PHASE2","title":"A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Dey","startDate":"2008-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":97},{"nctId":"NCT00685841","phase":"PHASE3","title":"A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-02","conditions":"COPD","enrollment":717},{"nctId":"NCT00846287","phase":"NA","title":"Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2008-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":16},{"nctId":"NCT01361984","phase":"PHASE4","title":"Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography","status":"UNKNOWN","sponsor":"University of California, Los Angeles","startDate":"2011-06","conditions":"Chronic Obstructive Pulmonary Disease, COPD, Emphysema","enrollment":20},{"nctId":"NCT00424528","phase":"PHASE4","title":"Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2006-12","conditions":"Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema","enrollment":235},{"nctId":"NCT00250679","phase":"PHASE3","title":"Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2005-10","conditions":"Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema","enrollment":443},{"nctId":"NCT00064402","phase":"PHASE3","title":"Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-04","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema","enrollment":741},{"nctId":"NCT00691405","phase":"PHASE2","title":"A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-10","conditions":"COPD","enrollment":215},{"nctId":"NCT00583947","phase":"PHASE2","title":"A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-01","conditions":"Asthma","enrollment":53},{"nctId":"NCT00571428","phase":"PHASE4","title":"Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2007-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":33},{"nctId":"NCT00685529","phase":"PHASE2","title":"Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2005-04","conditions":"COPD","enrollment":24},{"nctId":"NCT00064415","phase":"PHASE3","title":"To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-06","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema","enrollment":799},{"nctId":"NCT00460577","phase":"PHASE4","title":"Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03","conditions":"Acute Bronchial Obstruction, Asthma","enrollment":60},{"nctId":"NCT00507234","phase":"PHASE3","title":"Study in Subjects Greater Than 40 Years of Age With COPD","status":"COMPLETED","sponsor":"Dey","startDate":"2007-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":128},{"nctId":"NCT00280371","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate 20 Mcg/0.5 mL in the Treatment of Patients With COPD","status":"COMPLETED","sponsor":"Dey","startDate":"2006-01","conditions":"COPD","enrollment":345},{"nctId":"NCT00215436","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD","status":"COMPLETED","sponsor":"Dey","startDate":"2005-03","conditions":"COPD","enrollment":345},{"nctId":"NCT00403286","phase":"PHASE2","title":"A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Dey","startDate":"2006-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":457},{"nctId":"NCT00462540","phase":"PHASE3","title":"A Crossover Study in the Treatment of Patients With COPD","status":"COMPLETED","sponsor":"Dey","startDate":"2007-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":100},{"nctId":"NCT00308191","phase":"PHASE3","title":"A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD","status":"COMPLETED","sponsor":"Dey","startDate":"2006-04","conditions":"COPD","enrollment":128}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PERFOROMIST® 20 μg/ 2 mL vial, 1 vial BID"],"phase":"marketed","status":"active","brandName":"Formoterol Inhalation Solution","genericName":"Formoterol Inhalation Solution","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Chronic obstructive pulmonary disease (COPD), Asthma (maintenance therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}